Fate of Moderate Secondary Mitral Regurgitation in Patients Undergoing Aortic Valve Surgery for Severe Aortic Regurgitation
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 154
- 试验地点
- 1
- 主要终点
- Mortality for cardiac causes
研究概览
简要总结
Patients with severe aortic regurgitation (AR) may be affected, in many cases, by a concomitant moderate or severe mitral regurgitation (MR). Tethering of the mitral valve leaflets and/or annular dilatation, both consequences of left ventricular dilatation, represent the most common mechanisms underlying the development of MR which can therefore be defined as "secondary" in this case.
When both mitral and aortic regurgitation are severe, patients show a decreased survival due to the pathophysiological consequences of the combination of these pathological conditions. In this case, surgery on both diseased valves is required to interrupt the natural history of the disease and is widely supported by current guidelines. On the other hand, little is known about the fate and prognostic implications of moderate MR secondary to severe AR and whether or not it should be treated at the time of aortic valve surgery. For this condition, the current guidelines do not provide specific recommendations, referring generically to the decision of the Heart Team.
To date, there are few data describing the evolution of moderate MR in patients undergoing surgery for severe AR and insufficient data to support recommendations regarding the treatment of moderate MR concurrently with treatment of AR, so that this decision is now entrusted to the evaluation of the Heart Team. It is therefore desirable to evaluate the outcomes of these patients.
The aim of this study is to evaluate the short- and long-term fate of secondary moderate MR in patients undergoing aortic valve replacement for severe AR.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients;
- •Patients with severe aortic regurgitation (AR) AND moderate mitral regurgitation (MR).
- •Patients underwent isolated aortic valve surgery (Study Group) or concomitant mitral valve surgery (Control Group) and
- •Patients operated at the Cardiac Surgery Department of the San Raffaele Hospital from January 2004 to January 2019
排除标准
- •Patient with more than moderate MR
结局指标
主要结局
Mortality for cardiac causes
时间窗: Through study completion, an average of 7 years
次要结局
- Reintervention for severe AR recurrency(Through study completion, an average of 7 years)
- Severe AR recurrency(Through study completion, an average of 7 years)
- All causes mortality(Through study completion, an average of 7 years)
- Reintervention for severe MR(Through study completion, an average of 7 years)
研究者
Michele De Bonis
Chief of Cardiac Surgery of Advanced and Research Therapies
Ospedale San Raffaele
